Marstacimab: Treatment for Hemophilia A and B

Introduction

Hemophilia discovery has led to a better understanding of hemophilia A and B. Hemophilia A and B are conditions that make it hard for blood to clot. People with these conditions can bleed a lot, even from small injuries. The usual treatment is replacing missing blood clotting proteins, but this can be difficult and requires frequent IV (intravenous) treatments. Marstacimab is a new option that helps the blood clot in a different way. It works differently from older treatments by helping the blood clot better. Instead of getting frequent IV treatments, patients can take this medicine as a shot under the skin. It was approved in 2024 and has shown great results in studies. Let us know more in this article.

What Is Marstacimab?

1. A Medicine Designed for Hemophilia A and B: Marstacimab:

Marstacimab is a special type of medicine called a monoclonal antibody. It is made to help people with hemophilia A and B who are 12 years or older. Instead of replacing missing clotting proteins, it helps the body use the clotting proteins it already has. It is especially for those who do not have inhibitors from hemophilia treatment, which are things that stop other treatments from working.

2. How Does Marstacimab Work?

Marstacimab helps blood clot better by blocking a protein called TFPI (tissue factor pathway inhibitor). TFPI normally slows down blood clotting, which can sometimes cause too much bleeding. When Marstacimab stops TFPI from working too much, the blood can form clots more easily. This helps prevent too much bleeding and makes it safer for people with certain conditions. By improving blood clotting, Marstacimab allows people to do their daily activities without worrying about unexpected bleeding.

3. Why Is This Treatment Better?

Older treatments need frequent IV infusions, where medicine is given through a needle into a vein. This can be uncomfortable and take a lot of time. Marstacimab is different because it is given as a simple shot under the skin. This makes it much easier for people to take at home without needing special medical help. It also helps avoid problems like pain, infections, or damage to veins from IV treatments. With this new method, treatment is more comfortable and fits better into daily life.

FDA Approval Information

The following FDA (Food and Drug Administration) information is provided below:

1. When Was Marstacimab Approved?

The U.S. (United States) Food and Drug Administration (FDA) approved Marstacimab on October 11, 2024, for people with hemophilia A and B who are 12 years or older.

2. Is It Available in Other Countries?

The European Medicines Agency (EMA) approved Marstacimab in November 2024, and other countries are also reviewing it for approval.

Could Marstacimab be the long-awaited breakthrough that will allow hemophilia to be managed with fewer treatments? Let us know:

1. How Was It Tested?

Doctors studied Marstacimab in a trial with 116 patients (BASIS trial). They wanted to see how well it worked and if it was safe. The BASIS trial is a research study to see how well Marstacimab works and if it is safe for people with bleeding problems like hemophilia. In this study, doctors compare Marstacimab to older treatments to find out if it helps prevent bleeding better. Instead of using an IV, people in the trial get Marstacimab as a simple shot under the skin, which is easier to take. Doctors carefully watch the patients to see how well the medicine works and if there are any side effects. The goal of the BASIS trial is to find a better and easier treatment for people with bleeding disorders.

2. Primary and Secondary Endpoints

In the BASIS trial, researchers looked at different goals to see how well Marstacimab worked.

• Primary Endpoint: The main goal is to see if Marstacimab lowers the number of bleeding episodes a person has in a year. This is called the annualized bleeding rate (ABR).

• Secondary Endpoints: Researchers also check other important things, like whether the medicine is safe, if patients have any side effects, and how they feel about the treatment.

3. What Were the Main Results?

• Patients who switched from older treatments had much fewer bleeding episodes, going from 38 bleeds a year to only 3.2.

• It worked as well as the usual hemophilia treatments.

4. Was It Safe?

• Common Side Effects: Small skin reactions where the shot was given, headaches, and itching.

• Serious Risks: In rare cases, blood clots or allergic reactions could happen.

How Do You Take Marstacimab?

Knowing how to take Marstacimab the right way is important to make sure it works safely and effectively.

1. How Is It Given?

Marstacimab is a shot that is given under the skin. It comes in prefilled syringes or pens for easy use.

2. How Often Do You Take It?

• First, a 300 mg dose is given.

• Then, patients take 150 mg once a week.

3. Why Is This Easier for Patients?

Since it is taken only once a week as a small shot, it is much simpler than IV treatments that need to be done more often.

What Are the Risks of Taking Marstacimab?

1. Common Side Effects:

• Mild skin reactions where the shot is given.

• Headaches.

• Itching.

2. Serious Risks

• Blood Clots: Some people may develop dangerous clots.

• Allergic Reactions: Some may have a serious reaction to the medicine.

• Not Safe for Pregnant Women: Doctors do not recommend this for pregnant women because it could harm the baby.

3. Who Needs to Be Careful?

• People who have had blood clots (thrombosis) before should talk to their doctor before using Marstacimab.

• Like with other similar medicines, there is a chance that the body might react to Marstacimab. The immune system could make special proteins called antibodies that might also stop the medicine from working. Doctors will check for this to ensure that the treatment stays effective.

How Does Marstacimab Compare to Older Treatments?

1. Is It Better Than Factor Replacement Therapy?

• Unlike older treatments, Marstacimab does not require frequent IV (intravenous) infusions.

• It works just as well in preventing bleeding.

2. How Does It Compare to Other New Treatments?

• It is similar to a medicine called Emicizumab but works in a different way.

• Unlike other treatments, it does not need extra medications for certain bleeding problems.

3. Will It Be Used for More Conditions?

Doctors are studying if Marstacimab can help with more health problems. One thing they are looking at is whether it can stop unexpected bleeding that happens even during treatment. They also check to see if it can help people with other bleeding disorders. By learning more about how Marstacimab works, scientists hope to find new ways to help patients stay healthy and safe.

What Will Happen in the Future?

1. How Will Marstacimab Change Hemophilia Treatment?

Marstacimab will make life easier for people with hemophilia by reducing the need for IV infusions. Instead of getting medicine through a vein, patients can take it as a simple shot under the skin. This makes treatment quicker, less painful, and more convenient. With fewer hospital visits and less time spent on treatment, people with hemophilia can enjoy their daily activities, play sports, and spend time with family and friends. Marstacimab helps them live a more normal and active life while still staying healthy.

2. What Else Are Scientists Studying?

• Scientists are doing more research to learn how Marstacimab can help people. They are testing it to see if it works for other bleeding disorders, not just hemophilia. If it does, more people may be able to use this treatment to stay healthy.

• Doctors are also checking if Marstacimab stays safe and works well for many years. They want to make sure patients can use it for a long time without problems. By studying this medicine more, scientists hope to find better ways to help people with bleeding disorders live healthier and easier lives.

Conclusion

Marstacimab is an exciting new treatment that can help people with hemophilia A and B. It works by reducing bleeding, which makes life safer and easier for patients. One of the best things about this medicine is that it is much simpler to take than older treatments. Instead of getting IV infusions many times, patients can take Marstacimab as a quick shot under the skin just once a week. This makes treatment more comfortable and less stressful.

Because studies have shown strong results, Marstacimab could change how people manage hemophilia. It helps patients spend less time worrying about their treatment and more time enjoying their daily activities. As doctors continue to study it, Marstacimab is becoming a great option for many people who need a safe and effective way to control their bleeding.

Key Takeaway From iCliniq

• Marstacimab is a big step forward in treating hemophilia.

• It helps reduce the need for frequent IV infusions.

• Patients can take it as a simple shot under the skin.

• This makes treatment easier, more comfortable, and less time-consuming.

• It improves safety and quality of life for people with hemophilia A and B.

• Once-weekly dosing helps patients stick to their treatment plan.

• Studies show that it effectively reduces bleeding episodes.

• Ongoing research is exploring its long-term benefits and possible use for other conditions.